NCT03580655 · Interventional trial
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Overall registry status Completed
Phase 2
Conditions Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis With an Associated Hematologic Neoplasm
Delaware Valley sites
- University of Pennsylvania, Abramson Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory